PatientsVille.com Logo


Valproic Medical Research Studies

Up-to-date List of Valproic Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Valproic Medical Research Studies

Rank Status Study
1 Recruiting Molecular Signature of Valproic Acid in Breast Cancer With Functional Imaging Assessment - a Pilot
Condition: Cancer
Intervention: Drug: Valproic Acid
Outcome Measures: Determine if Valproic acid levels correlate with histone acetylation in leukocytes during treatment and whether either Valproic acid levels or histone acetylation in leukocytes predict histone acetylation in tumor samples post treatment.;   Assess the sensitivity and specificity of the genomic sensitivity signature of VPA (GDSS-VPA) to predict histologically measured antitumor activity of Valproic acid in newly diagnosed breast cancer.;   Analyze the change in immunohistochemical markers of proliferation, apoptosis, and tumor grade following treatment with Valproic acid in newly diagnosed breast cancer.;   Analyze the change in radiologic markers of tumor size and vascularity following treatment with Valproic acid in newly diagnosed breast cancer;   Analyze whether intrinsic breast subtype by the Breast Bioclassifier correlates with changes in tumor proliferation rate or changes in DCE-MRI markers of size and vascularity following treatment with Valproic acid.;   Determine if women have dose-limiting toxicities for Valproic acid over 7-12 days
2 Recruiting Bevacizumab, Temsirolimus, Valproic Acid, Cetuximab
Condition: Advanced Cancers
Interventions: Drug: Temsirolimus;   Drug: Bevacizumab;   Drug: Valproic Acid;   Drug: Cetuximab
Outcome Measures: Maximum Tolerated Dose (MTD) of Bevacizumab and Temsirolimus and/or Cetuximab or Valproic Acid;   Tumor Response
3 Recruiting Vidaza and Valproic Acid Post Allogeneic Transplant for High Risk AML and MDS
Conditions: Acute Myelogenous Leukemia AML;   Myelodysplastic Syndrome MDS
Intervention: Drug: Vidaza and Valproic Acid
Outcome Measures: Survival;   Disease Relapse
4 Recruiting Valproic Acid for the Prevention of Post-Amputation Pain
Conditions: Pain, Phantom;   Pain, Neuropathic
Interventions: Drug: Valproic Acid;   Other: Cherry Syrup
Outcome Measures: Efficacy of Valproic Acid in reducing the Incidence of chronic neuropathic and post-amputation pain.;   Neuropathic limb or post-amputation pain, and the incidence of pain sub-types;   Effect on analgesic requirement;   Qualitative characterization of pain sub-types
5 Recruiting Valproic Acid and Radiation Followed by Maintenance Valproic Acid and Bevacizumab in Children With High Grade Gliomas
Conditions: Glial Cell Tumors;   Malignant Gliomas;   Glioblastoma Multiforme;   Anaplastic Astrocytoma;   Gliomatosis Cerebri;   Gliosarcoma;   Brainstem Glioma
Interventions: Drug: Valproic acid;   Drug: Bevacizumab;   Radiation: Radiation therapy
Outcome Measures: Event free survival;   To determine toxicities of VPA when combined with radiation and when combined with bevacizumab in the post-radiotherapy phase.
6 Recruiting A Phase II Trial of Valproic Acid in Patients With Advanced Thyroid Cancers of Follicular Cell Origin
Condition: Thyroid Neoplasm
Intervention: Drug: Valproic Acid
Outcome Measures: To determine if Valproic acid will inhibit thyroid cancer growth, as evidenced by a decrease in thyroglobulin level, and tumor size.;   To determine if Valproic acid therapy will induce differentiation of and therefore increase uptake of radioactive iodine by the tumor cells. To determine the effect of Valproic acid on differentiation markers.
7 Recruiting Trial of Oral Valproic Acid for Retinitis Pigmentosa
Condition: Retinitis Pigmentosa
Interventions: Drug: Valproic Acid;   Drug: Placebo
Outcome Measures: Mean change in visual field area from baseline to 52 weeks.;   Static perimetry measurements in the full visual field;   Mean change in best corrected visual acuity.;   Color contrast sensitivity;   Mean change in peak Electroretinogram (ERG) amplitude;   Mean change in central macular thickness and macular volume;   Change in fundus appearance;   Mean change in total score on vision-related quality of life.;   Changes in clinical laboratory data;   Changes in physical examination findings
8 Unknown  Study of Efficacy and Safety of Valproic Acid in Chronic Lymphocytic Leukemia (CLL)
Condition: Chronic Lymphocytic Leukemia
Intervention: Drug: Valproic acid
Outcome Measures: Best clinical response as defined by NCIWG criteria for CLL;   Hematological toxicity (graded according to NCIWG criteria for CLL);   Non- hematological toxicity (graded according to NCI common toxicity criteria)
9 Recruiting Preoperative Valproic Acid and Radiation Therapy for Rectal Cancer
Condition: Colorectal Cancer
Interventions: Radiation: preoperative radiation therapy;   Drug: Valproic Acid;   Drug: Capecitabine
Outcome Measures: maximum tolerated dose of capecitabine, given alone or in combination with Valproic acid;   number of patients with complete pathological tumor regression;   overall survival;   number of patients alive with disease progression;   number of patients with pathologic complete response;   changes in quality of life from baseline
10 Recruiting A Phase II Study of Doxorubicin, Cyclophosphamide and Vindesine With Valproic Acid in Patients With Refractory or Relapsing Small Cell Lung Cancer After Platinum Derivatives and Etoposide
Condition: Small Cell Lung Carcinoma
Intervention: Drug: Adriamycin, cyclophosphamide, vindesine, Valproic acid
Outcome Measures: Six-months progression-free survival;   Survival;   Response rate;   Toxicity
11 Unknown  Valproic Acid in Treating Patients With Progressive, Non-Metastatic Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: Valproic acid;   Procedure: standard follow-up care
Outcome Measures: Percentage of patients exhibiting observed or predicted prostate-specific antigen (PSA) doubling time > 10 months after initiation of the study;   Duration of PSA response;   Percentage of patients who achieve a complete response;   Percentage of patients who achieve a partial response;   Self-perceived functionality, psychosocial well-being, and quality of life
12 Recruiting Disease Stabilization in AML by Treatment With ATRA, Valproic Acid and Low-dose Cytarabine
Condition: Acute Myelogenous Leukemia
Intervention: Drug: Cytarabine, all-trans retinoic acid, Valproic acid
Outcome Measures: Survival;   Disease stabilization;   Disease complications;   Side effects of therapy
13 Recruiting Valproic Acid With Chemoradiotherapy for Non-Small-Cell Lung Cancer
Condition: Locally Advanced Inoperable Non-small-lung Cancer
Intervention: Drug: Valproic acid
Outcome Measures: Toxicity;   Survival
14 Recruiting Valproic Acid and Platinum-based Chemoradiation in Locally Advanced Head and Neck Squamous Cell Carcinoma
Conditions: Head and Neck Cancer;   Oral Cavity Cancer;   Oropharyngeal Cancer
Intervention: Drug: Valproic Acid
Outcome Measures: Response Rate;   Adverse reactions to study treatment;   Progression free survival;   Overall survival;   Response rate comparison by p16 status;   Quality of life
15 Not yet recruiting Valproic Acid (VPA) vs Placebo
Condition: Breast Cancer
Interventions: Drug: Placebo;   Drug: Valproic Acid (VPA);   Behavioral: Questionnaires;   Behavioral: Pill Diary;   Behavioral: Drainage Diary
Outcome Measure: Time to Pleural Catheter Removal
16 Not yet recruiting Adjuvant Sunitinib or Valproic Acid in High-Risk Patients With Uveal Melanoma
Conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size;   Ciliary Body and Choroid Melanoma, Small Size;   Iris Melanoma;   Stage I Intraocular Melanoma;   Stage IIA Intraocular Melanoma;   Stage IIB Intraocular Melanoma;   Stage IIIA Intraocular Melanoma;   Stage IIIB Intraocular Melanoma;   Stage IIIC Intraocular Melanoma
Interventions: Drug: Sunitinib;   Drug: Valproic Acid
Outcome Measures: Overall survival;   Relapse-free survival;   Tolerability
17 Recruiting A Study to Evaluate the Safety and Tolerability of Valproic Acid in Healthy Volunteers or Trauma Patients
Conditions: Healthy Individuals Safety Study;   Shock,Hemorrhagic
Interventions: Drug: Valproic Acid;   Drug: Isotonic saline solution
Outcome Measure: Dose limiting toxicity (DLT)
18 Recruiting Bevacizumab, Chemotherapy and Valproic Acid in Advanced Sarcomas
Conditions: Sarcoma;   Soft Tissue Sarcoma;   Locally Advanced Sarcoma;   Unresectable Sarcoma;   Metastatic Sarcoma
Intervention: Drug: Bevacizumab, Gemcitabine, docetaxel and Valproic acid
Outcome Measure: Dose-limiting toxicities per CTCAE 4.0; grade 4 hematologic toxicity; grade 3 or 4 hepatotoxicity.
19 Unknown  Low Dose CdA Combined With Valproic Acid (VPA) in Previously Treated B-cell Chronic Lymphocytic Leukemia(B-CLL)
Condition: Chronic Lymphocytic Leukemia
Intervention: Drug: Valproic acid and 2-chlorodeoxyadenosine
Outcome Measures: To determine the tolerability of VPA in combination with low dose CdA in patients with advanced B-CLL;   minimal dose of VPA able to achieve adequate plasma levels of VPA and effective inhibition of VPA cellular targets, therapeutic response and survival , VPA pharmacokinetics
20 Not yet recruiting A Study to Compare the Effectiveness of Three Drugs, Fosphenytoin, Levetiracetam and Valproic Acid in Terminating Prolonged Seizures (Status Epilepticus) That do Not Respond to Benzodiazepines.
Condition: Status Epilepticus ( Prolonged Seizures) Not Responding to Benzodiazepines
Interventions: Drug: Fosphenytoin;   Drug: Levetiracetam;   Drug: Valproic acid
Outcome Measures: Clinical cessation of SE without life threatening hypotension or cardiac arrhythmias.;   Admission to ICU, intubation and mortality

These studies may lead to new treatments and are adding insight into Valproic etiology and treatment.

A major focus of Valproic research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss Valproic